Jefferies Slaps Buy Rating on Cogent Biosciences as FDA Accepts Bezuclastinib NDA for Non-Advanced Systemic Mastocytosis

Jefferies analyst started coverage on Cogent Biosciences with a Buy rating and $55 price target after the FDA accepted the NDA for bezuclastinib in Non-Advanced Systemic Mastocytosis. PDUFA date set for December 30, 2026.